Four novel genes that may significantly increase the risk of the most common form of late-onset Alzheimer’s have been identified by researchers at Massachusetts General Hospital and Harvard Medical School, as reported in the November 7th issue of American Journal of Human Genetics. The findings, part of a larger “Alzheimer’s Genome Project” (AGP) established three years ago to identify the full set of Alzheimer’s disease genetic risk factors, may lead to more aggressive therapeutic interventions to slow, stop or even reverse the effects of the disease. These new therapies would differ from current treatments that only address the symptoms of the disease.
The award co-sponsored by the Cure Alzheimer's Fund and the Alzheimer's Association honors the legacies of two pioneering Alzheimer researchers, George G. Glenner and Leon J. Thal. The two $100,000 grants will be made to early career researchers to inspire and enable innovative research which leads to effective therapies for Alzheimer's Disease.
Map of Alzheimer’s Genes May Lead to Novel Therapies
Dr. Rudolph Tanzi Speaks at International Conference on Alzheimer’s
Breakthrough genetic research to map all the genes connected to Alzheimer’s, which could lead to more aggressive treatment and a potential cure for the disease, was the focus of a presentation by leading Alzheimer’s researcher Dr. Rudolph Tanzi at the International Conference on Alzheimer’s Disease (ICAD) in Chicago.
No, Alzheimer’s is not a normal part of the aging process.
All parts of our bodies change as we age and this includes the brain. As people get older, they notice slowed thinking and changes in memory. However, the changes in memory associated with Alzheimer’s are not part of normal aging. Alzheimer’s disease is a progressive, irreversible and fatal brain disease.
It is rare to have an opportunity to combine a personal passion with something critical to the future of your family. Over the past year, I was fortunate to combine my passion for mountain climbing with a global effort to raise awareness and money for Alzheimer’s research.
Cure Alzheimer's Fund's Dr. Rudy Tanzi was recently featured on a recent PBS rebroadcast of 2004 Emmy award winning The Forgetting: A Portrait of Alzheimer's. Tanzi appeared on an expert panel in a newly produced 30-minute follow-up to provide up to the minute perspectives on current Alzheimer’s research, emerging drug therapies and caregiving.
The Forgetting is a pioneering example of how health programming can raise awareness, launch educational initiatives, and offer local connections and resources for viewers and their families.
Click here to view the show
June 8, 2008 Los Angeles Times opinion piece by author and Middlebury scholar Sue Halpern says the years of Alzheimer's research may be paying dividends with new treatments that will stave off the disease.
Halpern quotes Cure Alzheimer's Fund Dr. Rudy Tanzi explaining the disease: "The main place where a-beta 42 does its work is in the synapse. So every minute of the day, an Alzheimer patient is producing a-beta 42, for one reason or another, and it's accumulating in the brain ... it's accumulating ... in the synapse. Way, way before the plaques form, you get tiny little aggregates of a-beta 42. The peptides stick together and they get into the synapse and they disrupt the most basic synaptic function for learning and memory."
Click here to view the op-ed
Cure Alzheimer's Fund's Dr. Rudy Tanzi's submitted answers to Senator Hillary Rodham Clinton’s questions from the May 14, 2008, Senate Special Committee on Aging “The Future of Alzheimer’s: Breakthroughs and Challenges”
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.